Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 14/20 | 1.00 |
| ▸ | ADH1C | P00326 | 11/20 | 1.00 |
| ▸ | ADH4 | P08319 | 3/20 | 0.94 |
| ▸ | ADH1B | P00325 | 5/20 | 0.46 |
| ▸ | ADH7 | P40394 | 3/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclobutyl(Cyclopentyl)Formamide SCHEMBL4315833 | 1.00 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL14855293 | 0.97 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL39255 | 0.97 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL10913207 | 0.97 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL10013014 | 0.97 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL10012570 | 0.97 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL6005197 | 0.97 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL8745531 | 0.97 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL4496323 | 0.97 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL5122418 | 0.94 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1598331-B1 | Process for the preparation of phthalic acid dichloride | SALTIGO GMBH (DE) | 2009-07-15 | — | — | EP | claimed |
| US-7154003-B2 | Process for preparing phthaloyl chloride | LANXESS DEUTSCHLAND GMBH (DE) | 2006-12-26 | — | — | US | claimed |
| US-20050277788-A1 | Process for preparing phthaloyl chloride | LANXESS DEUTSCHLAND GMBH (DE) | 2005-12-15 | — | — | US | claimed |
| EP-1598331-A1 | Process for the preparation of phthalic acid dichloride | Lanxess Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | claimed |
| US-20250101241-A1 | ACTIVE ENERGY RAY CURABLE COMPOSITION | KJ CHEMICALS CORPORATION (JP) | 2025-03-27 | — | — | US | disclosed |
| EP-4435021-A1 | ACTIVE ENERGY RAY-CURABLE COMPOSITION | KJ Chemicals Corporation (JP) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024128000-A1 | ISOPOLYOXOTUNGSTATE SALT COMPOUND, SOLVATE THEREOF OR MIXTURE OF SAID COMPOUND AND SOLVATE, AND METHOD FOR PRODUCING SAID COMPOUND, SOLVATE OR MIXTURE | 東京応化工業株式会社 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024043261-A1 | AZO COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME | 日本化薬株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-11802208-B2 | Stilbene-based compound or salt thereof, and polarizing film, polarizing plate, and display device | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-116813979-A | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2023-09-29 | — | — | CN | disclosed |
| CN-112839988-B | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2023-06-06 | — | — | CN | disclosed |
| US-20230019461-A1 | POLARIZED LIGHT-EMITTING FILM CONTAINING WATER-SOLUBLE COUMARIN COMPOUND OR SALT THEREOF, POLARIZED LIGHT-EMITTING PLATE, AND DISPLAY DEVICE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2023-01-19 | — | — | US | disclosed |
| EP-0509302-A1 | Process for transfer of methine dyes | BASF Aktiengesellschaft (DE) | 1992-10-21 | — | — | EP | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
| US-4585774-A | Aniline derivatives and cardiotonic composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-29 | — | — | US | disclosed |
| EP-0064878-B1 | NOVEL ANILINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CARDIOTONIC COMPOSITIONS CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-07-24 | — | — | EP | disclosed |
| EP-0064878-A1 | Novel aniline derivatives, process for preparing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1982-11-17 | — | — | EP | disclosed |
| US-4252943-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-02-24 | — | — | US | disclosed |
| US-4217359-A | HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1980-08-12 | — | — | US | disclosed |
| US-4074057-A | HYPERLIPEMIA, DIABETES | TAKEDA CHEMICAL CO., LTD. (JA) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277788-A1 | Process for preparing phthaloyl chloride | PHYKPL, PFAS, PGLS | ADH1A 3390/4885ADH1C 2554/4885ADH4 3095/4885 |
| US-20250101241-A1 | ACTIVE ENERGY RAY CURABLE COMPOSITION | PARP1, CAP1, XRN2 | ADH1A 1300/4885ADH1C 2628/4885ADH4 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.